Regeneron
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a large-cap, but one that is still growing in virtually all directions. During its second-quarter, its widely popular eye injection, Eylea, is seeing demand approaching pre-pandemic levels. Meanwhile, the rest of the company's portfolio is expanding. Sales of Dupixent, an anti-inflammatory drug that treats allergies, increased by 70% year-over-year to nearly $1 billion during the quarter.
The company's skin cancer therapy, Libtayo, is under consideration to expand its range to treat various types of lung cancer as it is three more effective than existing drugs. If approved, this is a $25 billion market opportunity. Currently, Regeneron is in a superb financial position with $5.7 billion in cash and $1.5 billion in debt. This is how it was able to recently buy out Sanofi SA's (NASDAQ:SNY) entire stake for $5 billion, providing more future net income for its shareholders. Considering the company reinvests more than $2 billion annually into R&D efforts, there is no reason to doubt its growth prospects.
News 
Market Data 
Discover 
AI
